Investors

Overview

Tourmaline is a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases.

Change
Volume
May 18, 2024 12:39 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

background image

News

May 16, 2024
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
Read More
May 13, 2024
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Read More
March 19, 2024
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Read More

Events

November 6, 2023 3:50 PM EST
Guggenheim Healthcare 5th Annual I&I Conference
Read More
November 9, 2023 2:25 PM EST
Truist Securities BioPharma Symposium
Read More
November 14 - November 15, 2023
Jefferies London Healthcare Conference
Read More

Presentation

May 13, 2024
Tourmaline Corporate Overview - May 2024
Read More

Investor Information

Investor Contact

Lee M. Stern

Meru Advisors

lstern@meruadvisors.com